One stock that might be an intriguing choice for investors right now is Amedisys, Inc. (AMED) . This is because this security in the Medical - Outpatient and Home Healthcare space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking ...

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and est ...

Core Insights - Amedisys reported revenue of $570.79 million for Q4 2023, a year-over-year increase of 1.6% and an EPS of $0.94, down from $1.16 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $564.85 million by 1.05%, while the EPS fell short of the consensus estimate of $1.04 by 9.62% [1] Revenue Breakdown - Net Service Revenue from Home Health was $358.90 million, surpassing the average estimate of $356.95 million, reflecting a year-over-year increase of 4.8% [2] - Net Service Revenue from High Acuity Care was $5.90 million, matching the average estimate of $4.90 million, with no year-over-year change [2] - Net Service Revenue from Hospice reached $206 million, exceeding the average estimate of $200.35 million, representing a year-over-year increase of 4.3% [2] Stock Performance - Amedisys shares have returned -1.1% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3% [2] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [2]

Amedisys (AMED) came out with quarterly earnings of $0.94 per share, missing the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.62%. A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.08 per share when it actually produced earnings of $0.98, delivering a surprise of -9.26%.Over the ...

| --- | --- | |-------|-------------------------------------------------------------------------| | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | FORM 10-K | (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC. (E ...

Exhibit 99.1 AMEDISYS REPORTS FOURTH QUARTER AND YEAR-END 2023 FINANCIAL RESULTS BATON ROUGE, Louisiana (February 21, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 ◦ Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was diveste ...

The market expects Amedisys (AMED) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they mi ...

BATON ROUGE, La., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve the quality of ...

Financial Performance - Net service revenue for the three months ended September 30, 2023, was $556.2 million, a slight decrease of 0.3% compared to $558.0 million for the same period in 2022[21] - Operating income for the three months ended September 30, 2023, increased to $42.2 million, up 3.3% from $38.9 million in the same period last year[21] - Net income attributable to Amedisys, Inc. for the three months ended September 30, 2023, was $26.0 million, compared to $25.6 million for the same period in 2022, reflecting a growth of 1.4%[21] - Basic earnings per share for the three months ended September 30, 2023, was $0.80, compared to $0.79 for the same period in 2022, indicating a 1.3% increase[21] - Total operating expenses for the three months ended September 30, 2023, were $514.0 million, a decrease of 1.0% from $519.1 million in the same period last year[21] Expenses and Costs - The company incurred merger-related expenses of $5.0 million during the three months ended September 30, 2023[21] - Interest expense for the three months ended September 30, 2023, was $8.0 million, compared to $5.0 million for the same period in 2022, reflecting a 61.5% increase[21] - General and administrative expenses totaled $198.0 million, with home health at $91.4 million, hospice at $48.4 million, and high acuity care at $5.3 million[122] - The cost of service, including depreciation, amounted to $311.6 million, with home health at $201.6 million, hospice at $104.2 million, and high acuity care at $5.8 million[122] Cash Flow and Investments - Cash flows from operating activities for the nine months ended September 30, 2023, provided $76,877, compared to $92,400 for the same period in 2022[29] - The company reported a net cash increase of $39,883 for the nine months ended September 30, 2023[29] - The company made investments in technology assets totaling $6,881 during the nine months ended September 30, 2023[29] - The company has $550.0 million available under its Revolving Credit Facility, with $517.4 million available as of September 30, 2023[103] Revenue Sources - Approximately 73% of consolidated net service revenue for the three and nine-month periods ended September 30, 2023, was derived from Medicare, slightly down from 74% in the same periods of 2022[33] - For the three-month period ended September 30, 2023, Medicare revenue represented 39% of home health revenue, consistent with the same period in 2022[49] - Non-Medicare episodic-based revenue accounted for 7% of home health revenue for the three-month period ended September 30, 2023, unchanged from the same period in 2022[49] - Non-Medicare non-episodic-based revenue increased to 17% of home health revenue for the three-month period ended September 30, 2023, up from 13% in the same period of 2022[49] Mergers and Acquisitions - The company entered into a merger agreement with UnitedHealth Group on June 26, 2023, with Amedisys continuing as a wholly owned subsidiary[34] - Amedisys paid a termination fee of $106 million to Option Care Health, Inc. as part of the termination of a previous merger agreement, which was recorded as other income[82] - The company acquired regulatory assets of a home health provider for $0.4 million on January 20, 2023, recording $0.3 million in goodwill[84] - Goodwill recorded from the 2022 acquisition will be deductible for income tax purposes over approximately two to five years[87] Divestitures - The company divested its personal care business on March 31, 2023, which previously contributed to its revenue[33] - The company divested its personal care business for net proceeds of $47.8 million, recognizing a loss of $2.2 million during the three-month period ended March 31, 2023[93] Assets and Liabilities - The total balance as of September 30, 2023, was $1,093,518, with retained earnings of $728,603[26] - The total current assets decreased to $15.7 million as of September 30, 2023, from $22.3 million as of December 31, 2022, representing a decline of 29.66%[80] - Total assets decreased to $24.9 million as of September 30, 2023, compared to $31.6 million as of December 31, 2022, indicating a reduction of 21.43%[80] - Current liabilities increased to $8.1 million as of September 30, 2023, from $6.7 million as of December 31, 2022, marking a rise of 20.90%[80] Legal and Compliance - The company is involved in ongoing legal actions, but does not anticipate a material impact on its financial condition from these matters[108] - The company maintains various insurance programs but is self-insured for a substantial portion of potential claims, with exposure limits set for different types of insurance[115] Shareholder Information - The company repurchased 150,000 shares at a weighted average price of $115.64 per share, totaling approximately $17 million during the nine-month period ended September 30, 2022[128] - The 2023 Share Repurchase Program allows for up to $100 million in stock repurchases, with no shares repurchased as of September 30, 2023[128] - The company has not repurchased any shares under the 2023 Share Repurchase Program due to merger agreement limitations[128]

Exhibit 99.1 AMEDISYS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS BATON ROUGE, Louisiana (October 24, 2023) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and ninemonth periods ended September 30, 2023. Three-Month Periods Ended September 30, 2023 and 2022 ◦ Net service revenue decreased $1.8 million to $556.2 million compared to $558.0 million in 2022. Prior year included $16.6 million of net service revenue from our personal care business which was divested on March 31 ...